Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors
are essential for platelet activation. Antagonists against the P2Y12 receptor, which are
established in secondary prevention of myocardial infarction, have unexplained
anti-inflammatory effects. A novel P2Y12 receptor antagonist ticagrelor reduced
infection-related mortality compared to clopidogrel, previous standard treatment for patients
with myocardial infarction. Activated platelets release pro-inflammatory and procoagulant
platelet extracellular vesicles. The investigators assume that decrease in infection-related
mortality in patients treated with ticagrelor may be explained by greater inhibition of the
release of platelet vesicles by ticagrelor, compared to clopidogrel. This study is expected
to identify an additional mechanism of action of ticagrelor, which might contribute to the
observed clinical benefits in patients treated with ticagrelor.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Warsaw
Collaborator:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)